{"id":942225,"date":"2026-03-05T10:02:49","date_gmt":"2026-03-05T15:02:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/"},"modified":"2026-03-05T10:02:49","modified_gmt":"2026-03-05T15:02:49","slug":"cervomed-to-participate-in-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/","title":{"rendered":"CervoMed to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, March  05, 2026  (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March:<\/p>\n<p>\n        <strong>Leerink Global Healthcare Conference <\/strong><br \/>\n        <br \/>Format: 1&#215;1 Investor Meetings<br \/>Date: Wednesday, March 11, 2026<\/p>\n<p>\n        <strong>38<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual ROTH Conference<\/strong><br \/>\n        <br \/>Format: Fireside Chat &amp; 1&#215;1 Investor Meetings<br \/>Presentation Date: Monday, March 23, 2026<br \/>Presentation Time: 12:00 \u2013 12:30 PM PT<\/p>\n<p>The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bNL3MW_DWKEWoYCMT4cg0oqOIxGpvUt11fs8jNgQPVdxFceSojFEypy2N73GcMV9LlzQWy7Riyz0oqLYSHaGHCDGNva9_bYNspDYglP9BDhTQkzOf5wAqpeDSJUM1FlePTPk6pEF2iZvJQEpps5TJpCyFTZ8bTwEGhar0E6_vUn1Lna3IRkn2naM2WLTSEkewUf22vxbrbz3heE0kRFcIQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.cervomed.com\/news-events\/events-and-presentations<\/a><\/p>\n<p>\n        <strong>About CervoMed<\/strong><br \/>\n        <br \/>CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed\u2019s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026, subject to available funding.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contacts:<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Lisa Guiterman<br \/>Biongage Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ouJeyyYfe_BJQ4xxWw9Ty8HTB_wHKB_pZ-svyLPl65C6K5T7wFPcCVtYlnAWo5TIz6f7yiPEm1tKsR2ey7_2ryJ1Q5qmFdGcjkLbbe4xOZHMu_xUKMkqifCLtHlcIgbh\" rel=\"nofollow\" target=\"_blank\">lisa.guiterman@gmail.com<\/a><br \/>202-330-3431<\/p>\n<p>\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>Argot Partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_aZqWsbfAmNBkvi_Eq1Bpd6C2HznXSx59NjQ5yDnhjmcna6ZvtXS_ozGn8eTIQTtb-Iqavex3Ltf9NMcWIYn5DXyaljJXq_Bgg81F-Ri2WgRwEqTW2APNkxk8zOxfWOL\" rel=\"nofollow\" target=\"_blank\">cervomed@argotpartners.com<\/a><br \/>212-600-1902\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGM0YzkyMjAtZWYyOS00MzJiLThkYWMtMGZhZjg0Yjg5YzkzLTEwNDA1MTQtMjAyNi0wMy0wNS1lbg==\/tiny\/CervoMed-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, March 05, 2026 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March: Leerink Global Healthcare Conference Format: 1&#215;1 Investor MeetingsDate: Wednesday, March 11, 2026 38 th Annual ROTH Conference Format: Fireside Chat &amp; 1&#215;1 Investor MeetingsPresentation Date: Monday, March 23, 2026Presentation Time: 12:00 \u2013 12:30 PM PT The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https:\/\/ir.cervomed.com\/news-events\/events-and-presentations About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CervoMed to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942225","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CervoMed to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CervoMed to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, March 05, 2026 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March: Leerink Global Healthcare Conference Format: 1&#215;1 Investor MeetingsDate: Wednesday, March 11, 2026 38 th Annual ROTH Conference Format: Fireside Chat &amp; 1&#215;1 Investor MeetingsPresentation Date: Monday, March 23, 2026Presentation Time: 12:00 \u2013 12:30 PM PT The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https:\/\/ir.cervomed.com\/news-events\/events-and-presentations About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative &hellip; Continue reading &quot;CervoMed to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T15:02:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CervoMed to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-03-05T15:02:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/\"},\"wordCount\":203,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/\",\"name\":\"CervoMed to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM=\",\"datePublished\":\"2026-03-05T15:02:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CervoMed to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CervoMed to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"CervoMed to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"BOSTON, March 05, 2026 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March: Leerink Global Healthcare Conference Format: 1&#215;1 Investor MeetingsDate: Wednesday, March 11, 2026 38 th Annual ROTH Conference Format: Fireside Chat &amp; 1&#215;1 Investor MeetingsPresentation Date: Monday, March 23, 2026Presentation Time: 12:00 \u2013 12:30 PM PT The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https:\/\/ir.cervomed.com\/news-events\/events-and-presentations About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative &hellip; Continue reading \"CervoMed to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-05T15:02:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CervoMed to Participate in Upcoming Investor Conferences","datePublished":"2026-03-05T15:02:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/"},"wordCount":203,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/","name":"CervoMed to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM=","datePublished":"2026-03-05T15:02:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjA4MiM3NDY4NDg1IzIwMjg5NDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CervoMed to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942225"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942225\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}